Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia

Lefamulin is a novel pleuromutilin antibiotic with potent in vitro activity against key community-acquired bacterial pneumonia (CABP) pathogens. However, the clinical efficacy and safety of lefamulin for treating CABP remains unclear. An integrated analysis of 2 phase III trials investigating the cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Hung-Jen, Wang, Jui-Hsiang, Lai, Chih-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
4900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373590/
https://www.ncbi.nlm.nih.gov/pubmed/32702892
http://dx.doi.org/10.1097/MD.0000000000021223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373590/
https://www.ncbi.nlm.nih.gov/pubmed/32702892
http://dx.doi.org/10.1097/MD.0000000000021223

Ejemplares similares